Citi Reiterates Buy Rating on Abbott Labs (ABT)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Abbott Labs (ABT) PT Raised to $135 at JPMorgan
October 10, 2024 5:42 AM EDTJPMorgan analyst Robbie Marcus raised the price target on Abbott Labs (NYSE: ABT) to $135.00 (from $125.00) while maintaining a Overweight rating.
The analyst comments "Abbott is set to report 3Q24 results before the open on Wednesday, October 16. With volumes healthy, Fx modestly better, and price still a tailwind, we see... More
Oppenheimer Starts Abbott Labs (ABT) at Outperform
October 8, 2024 6:02 AM EDTOppenheimer analyst Suraj Kalia initiates coverage on Abbott Labs (NYSE: ABT) with a Outperform rating and a price target of $130.00.
The analyst comments "We are initiating coverage of Abbott Labs, a large-cap diversified healthcare play, with an OP... More



